Sirtuins as pharmacological targets in neurodegenerative and neuropsychiatric disorders

Author(s)

Leite, Jefferson A. ; Ghirotto, Bruno ; Targhetta, Vitor P. ; de Lima, Jean ; Camara, Niels O. S.

• Document type: Journal article
• Source: British Journal of Pharmacology; v. 179, n. 8, p. 16-pg., 2021-06-24.

Abstract

Histone deacetylases (HDACs) are enzymes that regulate several processes, such as transcription, cell proliferation, differentiation and development. HDACs are classified as either Zn2+-dependent or NAD(+)-dependent enzymes. Over the years, experimental and clinical evidence has demonstrated that HDAC modulation is a critical process in neurodegenerative and psychiatric disorders. Nevertheless, most of the studies have focused on the role of Zn2+-dependent HDACs in the development of these diseases, although there is growing evidence showing that the NAD(+)-dependent HDACs, known as sirtuins, are also very promising targets. This possibility has been strengthened by reports of decreased levels of NAD(+) in CNS disorders, which can lead to alterations in sirtuin activation and therefore result in increased pathology. In this review, we discuss the role of sirtuins in neurodegenerative and neuropsychiatric disorders as well the possible rationale for them to be considered as pharmacological targets in future therapeutic interventions. (AU)

• FAPESP's process: 17/05264-7 - Cell metabolism, microbiota and immune system: new paradigms in renal diseases physiopathology
• Grantee: Niels Olsen Saraiva Câmara
• Support Opportunities: Research Projects - Thematic Grants